All News

The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients, aged 1 month to 21 years.

Top news of the day across the health care landscape.

The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients

The National Hispanic Pharmacists Association was launched by the National Hispanic Health Foundation with public and private sector partners.

Biosimilars present a cost-saving opportunity for the health care system, but significant challenges inhibit uptake in the US market.

Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and MSD) for the maintenance treatment of adult patients with BRCA-mutated advanced ovarian cancer.

Top news of the day across the health care landscape.

Review highlights global patterns in excess body weight, drivers of the epidemic, and contribution to cancer burden.

With this approval, olaparib (Lynparza, AstraZeneca and MSD) is the first approved poly ADP ribose polymerase inhibitor for ovarian cancer.

The FDA granted an accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Officials with the FDA have granted accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

With the holiday season in full swing, managing your health might be the last thing on your mind.

Top news of the day across the health care landscape.

As is the case with any service-driven industry, the need to continually assess end-user satisfaction is paramount.

Durvalumab plus tremelimumab did not meet the primary endpoint of the phase 3 MYSTIC trial evaluating improvement in overall survival and progression-free survival compared with chemotherapy.

Top news of the day across the health care landscape.